Levodopa-carbidopa intestinal gel for treatment of advanced Parkinson's disease

Current Medical Research and Opinion

Volumn 27, Issue 5, 2011, Pages 907-919

  Fernandez, H H ^a   Odin, P ^b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Central Hospital   (Germany)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

continuous dopaminergic stimulation; dyskinesias; levodopa carbidopa intestinal gel; motor fluctuations; Parkinson's disease

Indexed keywords

CARBIDOPA PLUS LEVODOPA;

CONTINUOUS INFUSION; DRUG EFFICACY; DRUG SAFETY; GEL; HUMAN; PARKINSON DISEASE; QUALITY OF LIFE; REVIEW; UNIFIED PARKINSON DISEASE RATING SCALE;

ANTIPARKINSON AGENTS; CARBIDOPA; DRUG COMBINATIONS; HUMANS; LEVODOPA; MEDLINE; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79954520846     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.560146     Document Type: Review

References (83)

1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-35. (Pubitemid 44262284)
2. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the 'common' neurologic disorders. Neurology 2007;68:326-37. (Pubitemid 46188246)
3. De Rijk MC, Tzourio C, Breteler MM, et al. Prevalence parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON collaborative study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:10-15. (Pubitemid 27047434)
4. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999; 52:1214-20. (Pubitemid 29177924)
5. Driver JA, Logroscino G, Gaziano JM, et al. Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009;72:432-8.
6. Perez F, Helmer C, Dartigues JF. A 15-year population-based cohort study of the incidence of Parkinson's disease and dementia with Lewy bodies in an elderly French cohort. J Neurol Neurosurg Psychiatry 2010;81:742-6.
7. Barone P, Antonini A, Colosimo C, et al. PRIAMO study group. The Priamo study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 2009;11:1641-9.
8. Simuni T, Sethi K. Nonmotor manifestations of Parkinson's disease. Ann Neurol 2008;64(Suppl. 2):565-80.
9. Zahodne LB, Fernandez HH. Parkinson's psychosis. Curr Treat Options Neurol 2010;12:200-11.
10. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19:997-1005. (Pubitemid 39302831)
11. Hauser RA. Levodopa: past, present, and future. Eur Neurol 2009;62:1-8.
12. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62(Suppl. 1):S47-S55. (Pubitemid 38082852)
13. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-87. (Pubitemid 44081890)
14. Nyholm D. The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease. Parkinsonism Relat Disord 2007; 13(Suppl. 1):S13-17. (Pubitemid 47444538)
15. Stocchi F. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease. Parkinsonism Relat Disord 2009;15(Suppl. 1):S9-15.
16. Hauser RA, McDermott MP, Messing S; Parkinson Study Group. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756-60. (Pubitemid 44925085)
17. Chase TN. The significance of continuing dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998;55(Suppl. 1):1-9. (Pubitemid 28051032)
18. Antonini A, Tolosa E. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. Expert Rev Neurother 2009;9:859-67.
19. Nutt JG, Woodward WR, Hammerstad JP, et al. The 'on-off' phenomenon in Parkinson's disease. Relation to levodopa absorption and transport. N Engl J Med 1984;310:483-8. (Pubitemid 14189988)
20. Tolosa E, Mart́ MJ, Valldeoriola F, et al. History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 1998; 50(Suppl. 6):S2-10; discussion S44-8.
21. Lundqvist C. Continuous levodopa for advanced Parkinson's disease. Neuropsychiatr Dis Treat 2007;3:335-48. (Pubitemid 47215009)
22. Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalaline after inhibition of peripheral decarboxylase. Nature 1967;215:852-3.
23. Birkmayer W, Mentasti M. Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes) [in German]. Arch Psychiatr Nerveknr 1967;210:29-35.
24. Tissot R, Bartholini G, Pletscher A. Drug-induced changes of extracerebral dopa metabolism in man. Arch Neurol 1969;20:187-90.
25. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of 9 years' experience. Can Med Assoc J 1969;101:59-68.
26. Block G, Liss C, Reines S, et al. Comparison of immediate release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-7. (Pubitemid 27037728)
27. Poewe WH, Deuschl G, Gordin A, et al. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 2002;105:245-55. (Pubitemid 34407226)
28. Nyholm D, Askmark H, Gomes-Trolin C, et al. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol 2003;26:156-63. (Pubitemid 36676295)
29. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
30. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931-8.
31. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61:1044-53.
32. Rascol O, Brooks DJ, Brunt ER, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;3452:1484-91. (Pubitemid 30318272)
33. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45. (Pubitemid 28029850)
34. Holloway RG, Shoulson I, Fahn S, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-53. (Pubitemid 38915945)
35. Hauser RA, Rascol O, Korczyn AD, et al. Ten-year follow up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007;22:2409-17. (Pubitemid 351155989)
36. Rascol O, Brooks DL, Korczyn AD, et al. 056 Study Group. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. Mov Disord 2006;21: 1844-50. (Pubitemid 44848929)
37. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009;72(Suppl. 4):S1-136.
38. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Mov Disord 2010;25:858-66.
39. Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009;10:677-91.
40. Colpaert FC, Van Bever WF, Leysen JE. Apomorphine: chemistry, pharmacology, biochemistry. Int Rev Neurobiol 1976;19:225-68. (Pubitemid 8009834)
41. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004;23(6 Suppl. 4):S8-11.
42. Antonini A, Odin P. Pros and cons of apomorphine and L-dopa continuous infusion in advanced Parkinson's disease. Parkinson Relat Disord 2009; 155:S97-100.
43. Clarke CE, Worth P, Grosset D, et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkinson Relat Disord 2009;15:728-41.
44. Hardie RJ, Lees AJ, Stern GM. On-off fluctuations in Parkinson's disease: a clinical and neuropharmacological study. Brain 1984;107:487-506. (Pubitemid 14108832)
45. Nyholm D. Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease. Expert Rev Neurother 2006;6:1403-11. (Pubitemid 44696265)
46. Kurlan R, Rothfield KP, Woodward WR, et al. Erratic gastric emptying of levodopa may cause 'random' fluctuations of parkinsonian mobility. Neurology 1988;38:419-21. (Pubitemid 18083681)
47. Rabinak CA, Nirenberg JM. Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010;67:58-63.
48. European Parkinson's Disease Association. Duodopa- Intestinal Gel (levodopa\+carbidopa). Parkinson's Decision Aid. Available at: http://epda.eu. com/medinfo/duodopa/ [Last accessed 18 August 2010].
49. Papathanou M, Van der Laan R, Jenner P, et al. Pulsatile and continuous infusion of L-dopa induce abnormal involuntary movements in 6-OHDA-lesioned rats. Poster presented at The Movement Disorder Society's 14th Annual Congress of Parkinson's Disease and Movement Disorders; June 13-17, 2010, Buenos Aires, Argentina.
50. Bredberg E, Nilsson D, Johansson K, et al. Intraduodenal infusion of a waterbased levodopa dispersion for optimisation of the therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol 1993;45:117-22. (Pubitemid 23267413)
51. Stocchi F, Vacca L, Ruggieri S, et al. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 2005;62:905-10. (Pubitemid 40973452)
52. Devos D. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Mov Disord 2009;24:993-1000.
53. DANMODIS, Danish Movement Disorder Society; SWEMODIS, Swedish Movement Disorder Society. Duodopa: Scandinavian Consensus I. Treatment with levodopa/carbidopa gel (Duodopa-) in patients with Parkinson's disease, 2008. Available at: http://info.parkinsonforbundet.se/ wp-content/uploads/ duodopakonsensus-20081.pdf [Last accessed 18 August 2010].
54. Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64. (Pubitemid 46547018)
55. Sage JL, Trooskin S, Sonsalla PK, et al. Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism. Ann Neurol 1988;24:87-9.
56. Sage JL, Schuh L, Heikkila RE, et al. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol 1988;11:36-44. (Pubitemid 18039432)
57. Sage JL, Trooskin S, Sonsalla PK, et al. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinson's disease Neurology. 1989;39(11 Suppl. 2):60-3; discussion 72-3. (Pubitemid 20020582)
58. Nilsson D, Hansson LE, Johansson K, et al. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand 1998;97:175-83. (Pubitemid 28254914)
59. Kurth MC, Tetrud JW, Tanner CM, et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurology 1993;43:1698-703. (Pubitemid 23307938)
60. Nyholm D, Nilsson Remahl AI, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64:216-23.
61. Nyholm D, Constantinescu R, Holmberg B, et al. Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009;119:345-8.
62. Isacson D, Bingefors K, Kristiansen IS, et al. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand 2008;118:379-86.
63. Nilsson D, Nyholm D, Aquilonius SM. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand 2001; 104:343-8. (Pubitemid 33107378)
64. Nyholm D, Jansson R, Willows T, et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005; 65:1506-7. (Pubitemid 41552798)
65. Antonini A, Isaias IU, Canesi M, et al. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9. (Pubitemid 47067225)
66. Eggert K, Schrader C, Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008;31:151-66. (Pubitemid 351787111)
67. Antonini A, Mancini F, Canesi M, et al. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Dis 2008; 5:244-6. (Pubitemid 351347862)
68. Annic A, Devos D, Seguy D, et al. Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: efficacy and safety [in French]. Rev Neurol (Paris) 2009;165:718-27.
69. Raudino F, Garavaglia P, Pianezzola C, et al. Long-term experience with continuous duodenal levodopa-carbidopa infusion (Duodopa): report of six patients. Neurol Sci 2009;30:85-6.
70. Puente V, De Fabregues O, Oliveras C, et al. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life. Parkinsonism Relat Disord 2010;16:218-21.
71. Pälhagen SE, Dizdar N, Hauge TB, et al. Long-term study on clinical benefits and quality-of-life of intraduodenal levodopa in routine care for a cohort of treatment-na?̈ve patients with advanced Parkinson's disease. Poster presented at: 62nd Annual Meeting of the American Academy of Neurology, April 10-17 2010, Toronto, Canada.
72. Honig H, Antonini A, Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009;24:1468-74.
73. Sánchez-Castañeda C, Campdelacreu J, Miró J, et al. Cognitive improvement after duodenal levodopa infusion in cognitively impaired Parkinson's disease patients. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:250-1.
74. Nyholm D, Lewander T, Johansson A, et al. Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clin Neuropharmacol 2008;31:63-73. (Pubitemid 351489331)
75. Meppelink AM, Nyman R, Van Laar T, et al. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Mov Disord 2010: published online 19 October 2010, doi: 10.1002/ mds.23408.
76. Toth C, Brown MS, Furtado S, et al. Neuropathy as a potential complication of levodopa use in Parkinson's disease. Mov Disord 2008;23:1850-9.
77. Potack JZ, Chokhavatia S. Complications of and controversies associated with percutaneous endoscopic gastrostomy. Report of a case and literature review. Medscape J Med 2008;10:142.
78. Schrag SF, Sharma R, Jaik NP, et al. Complications related to percutaneous endoscopic gastrostomy (PEG) tubes. A comprehensive clinical review. J Gastrointestin Liver Dis 2007;16:407-18.
79. Lö ser C, Aschl G, Hé buterne X, et al. ESPEN guidelines on artificial enteral nutrition - percutaneous endoscopic gastrostomy (PEG). Clin Nutr 2005; 24:848-61.
80. Karlsborg M, Korbo L, Regeur L, et al. Duodopa pump treatment in patients with advanced Parkinson's disease. Dan Med Bull 2010;57:A4155.
81. Lipp A, Lusardi G. Systemic antimicrobial prophylaxis for percutaneous endoscopic gastrostomy. Cochrane Database Syst Rev 2006;CD005571.
82. Jafri NS, Mahid SS, Minor KS, et al. Meta-analysis: antibiotic prophylaxis to prevent peristomal infection following percutaneous endoscopic gastrostomy. Aliment Pharmacol Ther 2007;25:647-56.
83. Bronstein JM, Tagliati M, Alterman RL, et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol 2010: published online 11 October 2010, doi: 10.1001/ archneurol.2010.260